Physician profile
Ioana Chirca
NPI 1932494077
$3,590.08
in general payments reported to CMS, 2019-2025
22 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $364 · 2021: $409 · 2022: $586 · 2023: $463 · 2024: $353 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,021.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accelerate Diagnostics INC. | $500.00 | 2019 | |
| Merck Sharp & Dohme LLC | $481.59 | 2019-2025 | Dificid, Delstrigo, Zerbaxa |
| Melinta Therapeutics, LLC | $398.19 | 2019-2025 | Kimyrsa, Vabomere, Rezzayo |
| Astellas Pharma US INC | $381.98 | 2019-2024 | Cresemba |
| Abbvie INC. | $314.67 | 2020-2024 | Avycaz |
| Gilead Sciences, INC. | $299.46 | 2019-2023 | Epclusa |
| Shionogi INC | $277.11 | 2021-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $189.91 | 2022-2025 | Nuzyra |
| Allergan, INC. | $142.81 | 2019-2020 | |
| Janssen Biotech, INC. | $139.51 | 2021-2023 | Symtuza |
| Exthera Medical Corporation | $101.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $52.71 | 2019 | |
| Viiv Healthcare Company | $47.38 | 2023-2024 | Apretude, Dovato |
| Tetraphase Pharmaceuticals, INC. | $38.99 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $38.53 | 2024 | Xacduro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $38.00 | 2019-2022 | |
| Insmed, INC. | $33.79 | 2019 | |
| Cormedix INC. | $31.65 | 2025 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2023 | Cuvitru |
| Ferring Pharmaceuticals INC. | $22.20 | 2024 | Rebyota |
| Aimmune Therapeutics, INC. | $17.58 | 2024 | |
| Dynavax Technologies Corporation | $13.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ioana Chirca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.